{
    "clinical_study": {
        "@rank": "134749", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of naltrexone in the treatment of\n      cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2)\n      decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in\n      treatment."
        }, 
        "brief_title": "Naltrexone in Treatment of Cocaine Dependence - 5", 
        "condition": "Cocaine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "Double-blind, placebo controlled study of the safety and efficacy of naltrexone in treating\n      cocaine dependence in a patient sample that initiated the study while in an inpatient\n      setting and were then followed-up for 3 months as outpatients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Meet DSM-III-R criteria for cocaine dependency,\n\n          2. 18 to 65 years of age,\n\n          3. capable of understanding the study,\n\n          4. voluntarily signed consent,\n\n          5. male or non-pregnant female using approved form of birth control.\n\n        Exclusion Criteria:\n\n          1. abnormal liver function tests (SGOT, SGPT, or GGT greater than twice the normal\n             values),\n\n          2. opioid use within the last 7 days,\n\n          3. use of neuroleptics,\n\n          4. having a severe acute medical problem,\n\n          5. unable to complete psychiatric rating scales, or\n\n          6. judged by the investigator to be unlikely to comply with the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "April 18, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00015080", 
            "org_study_id": "NIDA-5-0012-5", 
            "secondary_id": "Y01-5-0012-5"
        }, 
        "intervention": {
            "intervention_name": "Naltrexone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "lastchanged_date": "November 3, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45220"
                }, 
                "name": "Cincinnati MDRU"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Naltrexone in Treatment of Cocaine Dependence", 
        "overall_official": {
            "affiliation": "Cincinnati MDRU", 
            "last_name": "Eugene Somoza, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "Retention"
            }, 
            {
                "measure": "Cocaine use"
            }, 
            {
                "measure": "Depression"
            }, 
            {
                "measure": "Anxiety"
            }, 
            {
                "measure": "Addiction severity"
            }, 
            {
                "measure": "Global improvement"
            }, 
            {
                "measure": "Psychopathology"
            }
        ], 
        "reference": {
            "citation": "Somoza, E., et al. A Double-Blind,Placebo Controlled Clinical Trial of Naltrexone as a Treatment for Cocaine Dependence. NIDA Research Monograph, 1998, 179, p. 295.. None"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00015080"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "Cincinnati MDRU", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1996"
    }, 
    "geocoordinates": {
        "Cincinnati MDRU": "39.103 -84.512"
    }
}